Please select the option that best describes you:

How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?  

What factors (i.e. timing from transplant, dose, prior therapy) impact your decision? 



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Agree on all fronts with @Ben Derman's excellent r...
Medical Oncologist at Northwest Georgia Oncology Centers
Our patients typically receive Dara RVD per GRIFFI...
Sign in or Register to read more